ClinicalTrials.gg
CompletedNCT06423703ALLEVIATE2Updated Jan 26, 2026

A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

A Phase 3 interventional study of Cebranopadol and Oxycodone IR in Acute Pain, sponsored by Tris Pharma, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Tris Pharma, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 351 studies in Acute Pain with a site in United States — 47 open to participants now, 53 under way, 1 of them phase 3. Acute Pain · United States.

Enrollment
64th of 320
240 · median 84
Started
2024
with 26 others
Phase 3
42 of 351
1 open now
Registered
307th of 351
by date

Among the 351 studies in Acute Pain with a site in United States, this one is the 64th largest by enrollment of the 320 interventional ones that give a count, is one of 27 that started in 2024, is one of 42 in phase 3, and was the 307th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

47 of the 351 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Acute Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.

Read the detailed description

This study is a Phase 3, multicenter, randomized, double-blind, placebo- and active-controlled parallel-group study to evaluate the efficacy and safety of cebranopadol in the treatment of postoperative pain following primary unilateral bunionectomy with first metatarsal osteotomy. The study will be conducted in 3 phases: Screening, Treatment, and Follow-up.

03

Conditions studied

  • Acute Pain

Browse trials for

Keywords

  • Bunionectomy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria Before Surgery:

  • Scheduled to undergo primary unilateral bunionectomy with first metatarsal osteotomy and internal fixation with no collateral procedures, using anesthesiologic and surgical procedures planned.
  • Must be able to adhere to the visit schedule, complete all study assessments and protocol requirements, including self-reported questionnaires.

Key Exclusion Criteria Before Surgery:

  • Any disease, medical condition, or laboratory finding that in the investigator's opinion may interfere with the study procedures or data integrity, or compromise the safety of the subject.
  • Secondary (i.e., unrelated to bunion) current painful condition that could confound the interpretation of efficacy, safety, or tolerability data in the study, in the opinion of the investigator.
  • Subjects who require any analgesic for secondary (i.e., unrelated to bunion) painful condition that might impact the subject's ability to properly assess their postoperative pain, or that may require treatment during the Treatment Phase.
  • History of allergy or to any opioid analgesics, anesthetics, ibuprofen, or other NSAIDs.

Immediate Postoperative Exclusion Criteria:

  • Surgical, postsurgical, or anesthetic complication that could confound the interpretation of efficacy, safety, or tolerability data in the study.
  • Deviation from the surgical, postsurgical, or anesthetic protocol that could confound the interpretation of efficacy, safety, or tolerability data in the study.
  • Evidence of hemodynamic instability or respiratory insufficiency.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Cebranopadol

    once daily for 3 days

    Drug: Cebranopadol · Drug: Placebo

  • Active comparator
    Oxycodone IR

    four times per day for 3 days

    Drug: Oxycodone IR

  • Placebo comparator
    Placebo

    four times per day for 3 days

    Drug: Placebo Only

Interventions

  • once daily for 3 days

    Also known as: TRN-228

  • four times per day for 3 days

    Also known as: oxycodone immediate release

  • DrugPlacebo Only

    four times per day for 3 days

  • DrugPlacebo

    three times per day for 3 days

06

What researchers measure

Primary outcomes

  1. Pain NRS area under the curve: cebranopadol vs. placebo

    Time frame: 2-48 hours

Secondary outcomes

  1. Proportion of subjects who require opioid rescue medication

    Time frame: 1-7 Days

  2. Global Assessment of Satisfaction

    Time frame: 1-7 Days

  3. Total oxycodone rescue consumption

    Time frame: 1-7 Days

Other outcomes

  1. Incidence of Respiratory Safety Events

    Time frame: 1-7 Days

07

Study locations

10 sites
  • ALLEVIATE 2 Site 001108
    Sheffield, Alabama 35660, United States
  • ALLEVIATE 2 Site 001106
    Little Rock, Arkansas 72211, United States
  • ALLEVIATE 2 Site 001103
    Tampa, Florida 33613, United States
  • ALLEVIATE 2 Site 001102
    Atlanta, Georgia 30331, United States
  • ALLEVIATE 2 Site 001107
    Overland Park, Kansas 66212, United States
  • ALLEVIATE 2 Site 001105
    Pasadena, Maryland 21122, United States
  • Alleviate 2 001113
    Houston, Texas 77043, United States
  • ALLEVIATE 2 Site 001104
    McAllen, Texas 78501, United States
  • ALLEVIATE 2 Site 001111
    San Antonio, Texas 78240, United States
  • ALLEVIATE 2 Site 001101
    Salt Lake City, Utah 84107, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jan 2025, 6 months.

Of 29 industry-sponsored phase 3 interventional studies under Acute Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 6 months is below that.

Counting every sponsor, half of 54 studies reached it within 14 months; a quarter within 7 and three quarters within 25.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
May 21, 2024
StartActual
Jul 18, 2024
Primary completionActual
Jan 31, 2025
CompletionActual
Jan 31, 2025
Results delay requested
Jan 14, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06423703
Lead sponsor
Tris Pharma, Inc.
Responsible party
Sponsor
First posted
May 21, 2024
Start date
Jul 18, 2024
Primary completion
Jan 31, 2025
Completion
Jan 31, 2025
Last update
Jan 26, 2026

Study contacts

Todd M Bertoch, MD
principal investigator · Cenexel JBR

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion